CL2008000865A1 - Compuestos derivados de benzimidazol-2-ona; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de un trastorno psicotico o un deterioro cognitivo. - Google Patents

Compuestos derivados de benzimidazol-2-ona; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de un trastorno psicotico o un deterioro cognitivo.

Info

Publication number
CL2008000865A1
CL2008000865A1 CL200800865A CL2008000865A CL2008000865A1 CL 2008000865 A1 CL2008000865 A1 CL 2008000865A1 CL 200800865 A CL200800865 A CL 200800865A CL 2008000865 A CL2008000865 A CL 2008000865A CL 2008000865 A1 CL2008000865 A1 CL 2008000865A1
Authority
CL
Chile
Prior art keywords
compounds
ona
benzimidazol
treatment
pharmaceutical composition
Prior art date
Application number
CL200800865A
Other languages
English (en)
Inventor
Ian Thomson Forbes
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38050489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000865(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2008000865A1 publication Critical patent/CL2008000865A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL200800865A 2007-03-29 2008-03-26 Compuestos derivados de benzimidazol-2-ona; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de un trastorno psicotico o un deterioro cognitivo. CL2008000865A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0706167.4A GB0706167D0 (en) 2007-03-29 2007-03-29 Compounds

Publications (1)

Publication Number Publication Date
CL2008000865A1 true CL2008000865A1 (es) 2008-10-03

Family

ID=38050489

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800865A CL2008000865A1 (es) 2007-03-29 2008-03-26 Compuestos derivados de benzimidazol-2-ona; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de un trastorno psicotico o un deterioro cognitivo.

Country Status (6)

Country Link
AR (1) AR065864A1 (es)
CL (1) CL2008000865A1 (es)
GB (1) GB0706167D0 (es)
PE (1) PE20090553A1 (es)
TW (1) TW200901979A (es)
WO (1) WO2008119721A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5209479B2 (ja) 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有するベンゾイミダゾロン類
ES2391107T3 (es) 2005-09-30 2012-11-21 Glaxo Group Limited Compuestos que tienen actividad en el receptor M1 y sus usos en medicina
AU2006296369B2 (en) 2005-09-30 2012-12-20 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
JP2010539217A (ja) 2007-09-20 2010-12-16 グラクソ グループ リミテッド Ｍ１受容体にて活性を有する化合物および医薬としてのそれらの使用
GB0718415D0 (en) 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2200468A1 (en) * 1994-10-27 1996-05-09 Wayne J. Thompson Muscarine antagonists
WO1997016186A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine agonists
EP1221443B1 (en) * 1999-10-13 2004-09-01 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
JP2005532361A (ja) * 2002-06-17 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症の治療用の眼科用組成物
GB0605786D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0605784D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
GB0706167D0 (en) 2007-05-09
WO2008119721A1 (en) 2008-10-09
AR065864A1 (es) 2009-07-08
PE20090553A1 (es) 2009-06-06
TW200901979A (en) 2009-01-16

Similar Documents

Publication Publication Date Title
CL2007002327A1 (es) Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc.
CL2007002974A1 (es) Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1.
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007001902A1 (es) Compuestos derivados de piridina sustituidas; composicion farmaceutica; y uso en el tratamiento de un trastorno de agregacion de plaquetas.
BRPI0714539A2 (pt) "formas farmacêuticas"
CL2007001630A1 (es) Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
RU2398586C3 (ru) Фармацевтическая композиция
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
CL2007002234A1 (es) Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2007003552A1 (es) Compuestos derivados de pirimidina y piridina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno proliferativo celular.
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
DK1868579T3 (da) Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
CL2007002640A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2007002642A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
CL2007003202A1 (es) Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2007002431A1 (es) Compuestos derivados de azabenzotiofenil; composicion farmaceutica; y uso para la inhibicion del crecimiento celular anomalo o de tratamiento de un trastorno hiperproliferativo.
BRPI0813770A2 (pt) Composição, e, uso de uma composição
DK2079485T3 (da) Phenylpropionamidforbindelser og anvendelsen deraf
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas
BRPI0814555A2 (pt) O uso de compostos à base de lantibiótico com atividade antimicrobiana